Euroapi (EAPI) Aandelenoverzicht
Euroapi S.A. ontwikkelt, produceert, verkoopt en distribueert actieve farmaceutische ingrediënten en tussenproducten die worden gebruikt bij de formulering van geneesmiddelen voor menselijk en diergeneeskundig gebruik. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor EAPI uit onze risicocontroles.
EAPI Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Euroapi S.A. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €1.25 |
| 52 Week Hoogtepunt | €3.44 |
| 52 Week Laag | €1.22 |
| Bèta | 0.98 |
| 1 maand verandering | -0.63% |
| 3 maanden verandering | -0.79% |
| 1 Jaar Verandering | -61.06% |
| 3 jaar verandering | -87.72% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -90.72% |
Recent nieuws en updates
Narratiefupdate • Jun 30
EAPI: Reset Expectations And Higher Future P/E Could Support Rebound
Analysts have reduced their fair value estimate for Euroapi, cutting the price target from €2.00 to about €1.48. This is broadly in line with a recent move by the Street to bring targets down toward €1.70 as they factor in weaker revenue growth expectations and revised profitability assumptions alongside a higher future P/E multiple.
Narratiefupdate • Jun 16
EAPI: Revenue Contraction And Margin Pressure Will Continue To Restrain Future Earnings
Euroapi's analyst price target has been cut by €1.20 to €1.70, as analysts point to updated expectations for revenue contraction, profit margins, and a lower future P/E multiple. Analyst Commentary on Euroapi The latest research on Euroapi highlights a more cautious stance, with a reduced price target and a Neutral rating that suggests limited conviction in a strong near term recovery.Narratiefupdate • Jun 02
EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings
Analysts have cut Euroapi's price target sharply, with recent revisions moving from €2.90 to a range of €1.70 and €1. This reflects more cautious assumptions on revenue trends, margins and a higher P/E multiple applied to the stock.Narratiefupdate • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.Recent updates
Narratiefupdate • Jun 30
EAPI: Reset Expectations And Higher Future P/E Could Support Rebound
Analysts have reduced their fair value estimate for Euroapi, cutting the price target from €2.00 to about €1.48. This is broadly in line with a recent move by the Street to bring targets down toward €1.70 as they factor in weaker revenue growth expectations and revised profitability assumptions alongside a higher future P/E multiple.Narratiefupdate • Jun 16
EAPI: Revenue Contraction And Margin Pressure Will Continue To Restrain Future Earnings
Euroapi's analyst price target has been cut by €1.20 to €1.70, as analysts point to updated expectations for revenue contraction, profit margins, and a lower future P/E multiple. Analyst Commentary on Euroapi The latest research on Euroapi highlights a more cautious stance, with a reduced price target and a Neutral rating that suggests limited conviction in a strong near term recovery.Narratiefupdate • Jun 02
EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings
Analysts have cut Euroapi's price target sharply, with recent revisions moving from €2.90 to a range of €1.70 and €1. This reflects more cautious assumptions on revenue trends, margins and a higher P/E multiple applied to the stock.Narratiefupdate • May 10
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Euroapi's analyst price target has shifted lower from about €3.08 to €2.00, with analysts pointing to Deutsche Bank's recent cut in its target to €1, along with updated views on revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary Bullish Takeaways Bullish analysts may see the lower price target range, now clustering around €1 to €2, as setting a more conservative bar for execution, which can reduce the risk of further valuation resets if expectations are now better aligned with current fundamentals.Narratiefupdate • Apr 22
EAPI: Lower Demand And Portfolio Cuts Will Weigh On Future Earnings
Analysts have cut their price target on Euroapi to €1 from €2, with the change framed around more cautious assumptions despite essentially unchanged fair value, discount rate, revenue growth, profit margin and future P/E inputs in the latest update. Analyst Commentary Bearish analysts cutting the price target on Euroapi to €1 from €2 are signaling a more cautious stance around the stock, even though their core valuation inputs such as fair value frameworks, discount rate, revenue growth, profit margin and future P/E assumptions are described as essentially unchanged.
Narratiefupdate • Apr 08
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Analysts now see Euroapi's fair value closer to €2.90, down from €3.50, aligning with a series of lower Street price targets that most recently moved from €2.50 to €2 and then to €1. Analyst Commentary The recent cuts in fair value and Street targets to around €1 to €2 signal a cautious stance from research desks, with the most recent change bringing the target to €1 and maintaining a Sell view.Narratiefupdate • Mar 25
EAPI: Weaker 2026 Outlook And Portfolio Cuts Will Pressure Earnings Quality
Analysts have cut their price target on Euroapi to €1 from €2, with the shift broadly tied to ongoing caution reflected in recent research commentary that maintains a Sell stance and modest adjustments to revenue growth and profit margin assumptions. Analyst Commentary Recent research updates highlight a series of price target cuts on Euroapi, with bearish analysts reducing their fair value estimates while maintaining a cautious stance on the shares.Narratiefupdate • Mar 10
EAPI: Weaker 2025 Guidance Will Pressure Margins And Future Earnings Quality
Analysts have cut their Euroapi price target from €2 to €1, reflecting updated assumptions that now factor in lower revenue growth expectations, much slimmer profit margins, and a significantly higher future P/E multiple. Analyst Commentary Recent price target revisions point to a cautious stance from bearish analysts, who appear focused on execution risks and the implications for Euroapi's valuation.Narratiefupdate • Feb 24
EAPI: Lower 2025 Guidance And Reduced Multiple Will Shape Return Profile
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing updated assumptions on modest revenue growth, slightly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent research points to a more cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.Narratiefupdate • Feb 09
EAPI: Lower 2025 Outlook And Cautious Stance Will Shape Return Profile
Analysts have lowered their price target on Euroapi from €2.50 to €2, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that collectively suggest a more cautious valuation stance. Analyst Commentary Bearish analysts have recently cut their price target on Euroapi from €2.50 to €2.Narratiefupdate • Jan 25
EAPI: Execution Risks And Lower Outlook Will Shape Future Return Profile
Narrative update Analysts have trimmed their price target on Euroapi by €0.50 to €2.00, citing updated assumptions on revenue growth, profit margins and forward P/E that keep their stance cautious on the shares. Analyst Commentary Recent research has reinforced a cautious stance on Euroapi, with bearish analysts trimming their price targets to €2.00.Narratiefupdate • Jan 10
EAPI: Lower Profitability Assumptions And New Partnership Will Shape Future Returns
Analysts have trimmed their price target on Euroapi to €2 from €2.50, citing softer assumptions around revenue growth, profit margins and a higher future P/E multiple as the key drivers of the reset. Analyst Commentary Bearish analysts are signalling a cautious stance on Euroapi by aligning around a lower price target of €2, narrowed from €2.50.Narratiefupdate • Dec 19
EAPI: Higher Discount Rate Will Outweigh Benefits From New Corticosteroid Partnership
Analysts have slightly reduced their Euroapi price target, reflecting a modest reassessment of fair value. This adjustment accounts for a higher discount rate, even as long term profit margin assumptions edge up and revenue declines appear marginally less severe.Analyseartikel • Dec 18
Calculating The Intrinsic Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €2.68 Euroapi's €2.40 share...Analyseartikel • Dec 18
Euroapi S.A. (EPA:EAPI) Not Doing Enough For Some Investors As Its Shares Slump 26%
Euroapi S.A. ( EPA:EAPI ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Analyseartikel • Oct 03
Euroapi (EPA:EAPI) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Aug 02
Euroapi S.A. (EPA:EAPI) Just Released Its Interim Results And Analysts Are Updating Their Estimates
It's been a mediocre week for Euroapi S.A. ( EPA:EAPI ) shareholders, with the stock dropping 12% to €2.79 in the week...
Nieuw narratief • Mar 31
Capacity Expansion And Efficiency Improvements Will Shape Future Success
Euroapi focuses on high-margin differentiated APIs and CDMO services to boost sustainable revenue and profit margins through strategic project expansions.Analyseartikel • Mar 06
Analyst Estimates: Here's What Brokers Think Of Euroapi S.A. (EPA:EAPI) After Its Annual Report
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Analyseartikel • Oct 04
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Key Insights The projected fair value for Euroapi is €2.62 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Jul 29
There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Euroapi S.A. ( EPA:EAPI ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...Analyseartikel • May 24
Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Those holding Euroapi S.A. ( EPA:EAPI ) shares would be relieved that the share price has rebounded 29% in the last...Analyseartikel • Apr 10
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Mar 03
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
The Euroapi S.A. ( EPA:EAPI ) share price has fared very poorly over the last month, falling by a substantial 31%. For...Analyseartikel • Mar 02
Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Euroapi S.A. ( EPA:EAPI ) shares in the week since it released its yearly report, with...Analyseartikel • Dec 21
A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €5.03 With €5.47 share price...Analyseartikel • Aug 04
Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
It's been a good week for Euroapi S.A. ( EPA:EAPI ) shareholders, because the company has just released its latest...Analyseartikel • Aug 02
Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Euroapi fair value estimate is €24.50 Euroapi is estimated to...Analyseartikel • Jun 16
Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
When close to half the companies operating in the Pharmaceuticals industry in France have price-to-sales ratios (or...Rendement voor aandeelhouders
| EAPI | FR Pharmaceuticals | FR Markt | |
|---|---|---|---|
| 7D | -6.3% | 2.5% | -0.7% |
| 1Y | -61.1% | -3.9% | 0.7% |
Rendement versus industrie: EAPI presteerde slechter dan de French Pharmaceuticals -sector, die het afgelopen jaar een rendement van -3.9 % opleverde.
Rendement versus markt: EAPI presteerde slechter dan French Market, dat het afgelopen jaar een rendement van 0.7 % opleverde.
Prijsvolatiliteit
| EAPI volatility | |
|---|---|
| EAPI Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in FR Market | 10.9% |
| 10% least volatile stocks in FR Market | 2.5% |
Stabiele aandelenkoers: EAPI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de French markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van EAPI is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2020 | 2,961 | David Seignolle | www.euroapi.com/en |
Euroapi S.A. ontwikkelt, produceert, verkoopt en distribueert actieve farmaceutische ingrediënten en tussenproducten die worden gebruikt bij de formulering van geneesmiddelen voor menselijk en diergeneeskundig gebruik. Het bedrijf biedt een organisatie voor contractontwikkeling voor verschillende klassen van middelen die gebruikmaakt van vaste-fasechemie; deeltjesengineering; microbiële fermentatie; synthese van kleine moleculen; prostaglandinen; steroïden en hormonen; en opiaten en gereguleerde stoffen, evenals lipiden. Het bedrijf biedt zijn producten aan farmaceutische bedrijven, fabrikanten van generieke geneesmiddelen, fabrikanten van diergeneesmiddelen, bedrijven die zich bezighouden met consumentengezondheid, voeding en cosmetische producten, biotechbedrijven en distributiebedrijven, evenals aan contractontwikkelings- en productieorganisaties.
Euroapi S.A. Samenvatting
| EAPI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €119.37m |
| Inkomsten(TTM) | -€211.20m |
| Inkomsten(TTM) | €852.60m |
0.1x
P/S-verhouding-0.6x
Koers/WinstverhoudingIs EAPI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| EAPI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €852.60m |
| Kosten van inkomsten | €707.70m |
| Brutowinst | €144.90m |
| Overige uitgaven | €356.10m |
| Inkomsten | -€211.20m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
Jul 29, 2026
| Winst per aandeel (EPS) | -2.22 |
| Brutomarge | 17.00% |
| Nettowinstmarge | -24.77% |
| Schuld/Eigen Vermogen Verhouding | 5.8% |
Hoe presteerde EAPI op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/08 16:49 |
| Aandelenkoers aan het einde van de dag | 2026/07/08 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Euroapi S.A. wordt gevolgd door 11 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Justin Steven Smith | Bernstein |
| Patrick Andrew Wood | BofA Global Research |
| Fynn Scherzler | Deutsche Bank |